glp-1 drugs tirzepatide Menopause Hormone Therapy May Boost Drug Benefits How Does Tirzepatide Work? |
Description
Detailed Category Analysis# Receptor Targets# Retatrutide : Triple agonist: GIP, GLP-1, and glucagon receptors simultaneously Tirzepatide : Dual agonist: GIP and GLP-1 receptors Advantage : Retatrutide Weight Loss Efficacy# Retatrutide : Up to 28.7% body weight reduction at 68 weeks (Phase 3 TRIUMPH-4)
For semaglutide , a phase 2 trial published in the New England Journal of Medicine (2021) examined daily semaglutide 0.4 mg in NASH patients and found that 59% achieved NASH resolution compared to 17% with placebo
Takikawa M, Kurimoto Y, Tsuda T
At 52 weeks, the eGFR decline was 1.1 in the dulaglutide (1.5 mg) group, 1.5 in the dulaglutide (0.75 mg) group, and 2.9 in the glargine group
In in vitro studies of the effects of GLP-1 on pancreatic cells, GLP-1-treated human islets showed increased level of bcl-2 protein and decreased level of caspase-3 protein54)
( I ) Quantification of glucose oxidation in caECs pretreated with 100 nM GLP-1(2836) or scrambled control for 20 minutes
